| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 05/02/2002 | WO2002002091A3 Methods and compositions for the treatment of alcoholism and alcohol dependence |
| 05/02/2002 | WO2001098330A3 A RECOMBINANT CELL LINE EXPRESSING GPCRx11 AS A FUNCTIONAL RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING OF AGONISTS AND ANTAGONISTS |
| 05/02/2002 | WO2001096283A3 Hiv integrase inhibitors |
| 05/02/2002 | WO2001095739A3 Diet which induces ketosis in a canine or feline |
| 05/02/2002 | WO2001094586A3 Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
| 05/02/2002 | WO2001092282A3 Methods and compositions for treating flaviviruses and pestiviruses |
| 05/02/2002 | WO2001091774A3 Method of treating chronic ulcers |
| 05/02/2002 | WO2001091773A3 Method of stimulating hair growth |
| 05/02/2002 | WO2001083710A3 Clearance of neoplastic cells from mixed cellular compositions using viruses |
| 05/02/2002 | WO2001083555A3 Pain signaling molecules |
| 05/02/2002 | WO2001081298A3 Cyclic carboxylic acids as integrin antagonists |
| 05/02/2002 | WO2001077137A9 Albumin fusion proteins |
| 05/02/2002 | WO2001074900A3 Nuclear factor kb inducing factor |
| 05/02/2002 | WO2001072778A3 Method of identifying inhibitors of tie-2 |
| 05/02/2002 | WO2001070771A3 Acute neuronal induced calcium binding protein type 1 ligand |
| 05/02/2002 | WO2001070733A3 Di-substituted iminoheterocyclic compounds |
| 05/02/2002 | WO2001064741A3 Methods for selectively modulating survivin apoptosis pathways |
| 05/02/2002 | WO2001062923A3 Transporters and ion channels |
| 05/02/2002 | WO2001062289A3 Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant |
| 05/02/2002 | WO2001061009A3 Polypeptides and nucleic acids encoding same |
| 05/02/2002 | WO2001061008A3 Polypeptides and nucleic acids encoding same |
| 05/02/2002 | WO2001055210A3 Human cyr61 |
| 05/02/2002 | WO2001048209A3 Genes identified as required for proliferation of e. coli |
| 05/02/2002 | WO2001046394A3 Mammalian protein phosphatases |
| 05/02/2002 | WO2001044264A3 Novel stromelysin inhibitors |
| 05/02/2002 | WO2001042207A3 Novel methods for the treatment and prevention of ileus |
| 05/02/2002 | WO2001039762A3 Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system |
| 05/02/2002 | WO2001029070A3 Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
| 05/02/2002 | WO2001024828A3 MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN αVβ3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY |
| 05/02/2002 | WO2001018172A3 Fibroblast growth factor-like polypeptides |
| 05/02/2002 | WO2001009121A3 2-pyrazolin-5-ones_as tyrosine kinase inhibitors |
| 05/02/2002 | WO2000078972A3 Regulation with binding cassette transporter protein abc1 |
| 05/02/2002 | WO2000075365A9 COMPOUNDS AND METHODS TO ENHANCE rAAV TRANSDUCTION |
| 05/02/2002 | US20020053091 Isolated human G-protein coupled receptors, nucleic acid molecules encoding human GPCR proteins, and uses thereof |
| 05/02/2002 | US20020052594 Method and kit for imaging and treating organs and tissues |
| 05/02/2002 | US20020052513 Oxamide IMPDH inhibitors |
| 05/02/2002 | US20020052508 Heterocyclic thioamide derivatives |
| 05/02/2002 | US20020052504 N-((2-cyclopropoxy-5-(1H-tetrazol-1-))phenyl)methyl-2-(4 -phenyl)piperidin-3-amine and derivatives; in particular as neurokinin-1 receptor antagonists; analgesics; migraines; antiinflammatory, anxiolytic, emetic agents; antidepressants |
| 05/02/2002 | US20020052475 Cytokines for use in the treatment of autoimmune disease, inflammation, arthritis and multiple sclerosis |
| 05/02/2002 | US20020052417 Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use |
| 05/02/2002 | US20020052409 Compounds and methods for treating mitochondria-associated diseases |
| 05/02/2002 | US20020052407 Modulating expression, production, or formation of amyloid precursor protein by administering a nonsteroidal antiinflammatory agent that is a cyclooxygenase inhibitor |
| 05/02/2002 | US20020052404 Compositions and methods for treating or preventing diseases of body passageways |
| 05/02/2002 | US20020052400 Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. |
| 05/02/2002 | US20020052398 Pharmaceutical composition of 6-amino EM-12 |
| 05/02/2002 | US20020052397 Treatment of diseases characterized by excess Th2 cytokines and/ or an excess IgE production. |
| 05/02/2002 | US20020052393 Benzanilides as potassium channel openers |
| 05/02/2002 | US20020052391 Tetrahydroquinoline derivatives as glycine antagonists |
| 05/02/2002 | US20020052387 5-Substituted 2-aryl-4-pyrimidinones |
| 05/02/2002 | US20020052386 Pyrimidine derivatives |
| 05/02/2002 | US20020052381 Method of using diketopiperazines and composition containing them |
| 05/02/2002 | US20020052378 Novel compounds and compositions as protease inhibitors |
| 05/02/2002 | US20020052376 Imidazole derivatives and their use as farnesyl protein transferase inhibitors |
| 05/02/2002 | US20020052373 D4 dopamine receptor in combination with an acetylcholine esterase inhibitor. |
| 05/02/2002 | US20020052372 Using neurotrophic pipecolic acid derivative compounds having an affinity for FKBP-type immunophilins as inhibitors of the enzyme activity associated with immunophilin proteins |
| 05/02/2002 | US20020052370 Including the treatment of female sexual dysfunction especially female sexual arousal disorder |
| 05/02/2002 | US20020052369 Indolinone derivatives as protein kinase/phosphatase inhibitors |
| 05/02/2002 | US20020052366 Administering taurolidine, taurultam, or a biologically active derivative; induces tumor cell death by apoptosis. |
| 05/02/2002 | US20020052365 Selective anxiolytic therapeutic agents |
| 05/02/2002 | US20020052364 Condensed 2,3-benzodiazepine derivatives and their use as AMPA-receptor inhibitors |
| 05/02/2002 | US20020052358 Methods and compositions related to modulators of annexin and cartilage homeostasis |
| 05/02/2002 | US20020052357 Cyclic oxyguanidine pyrazinones as protease inhibitors |
| 05/02/2002 | US20020052356 Quinoline and quinazoline derivatives; prophylaxis or treatment of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity. |
| 05/02/2002 | US20020052351 Novel medical use for tachykinin antagonists |
| 05/02/2002 | US20020052349 p-(sulfonyl) aryl and heteroarylamines as anti-inflammatory agents |
| 05/02/2002 | US20020052348 Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase |
| 05/02/2002 | US20020052347 Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates |
| 05/02/2002 | US20020052346 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) |
| 05/02/2002 | US20020052344 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase IB (PTP-IB) |
| 05/02/2002 | US20020052341 Bupropion metabolites and methods of their synthesis and use |
| 05/02/2002 | US20020052340 Treating disorders ameliorated by inhibition of neuronal monoamine reuptake, such as erectile dysfunction, affective disorders, cerebral function disorders, cigarette smoking, and incontinence. |
| 05/02/2002 | US20020052337 Composition and method for inhibiting platelet aggregation |
| 05/02/2002 | US20020052323 Protease inhibitors, particularly for caspase enzyme; treating arthritis, ALS, MS, and the like. |
| 05/02/2002 | US20020052317 Anti-viral and anti-tumor chemotherapy by administration of erythropoeitin |
| 05/02/2002 | US20020052316 Bax-mediated apoptosis modulating reagents and methods |
| 05/02/2002 | US20020052315 Conformationally constrained backbone cyclized somatostatin analogs |
| 05/02/2002 | US20020052311 Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| 05/02/2002 | US20020051822 Enhancing bone formation, inhibiting osteoclastic differentiation or activating osteoblastic differentialation by administering to a human or animal suffering from, or susceptible to bone disease a lanthanum compound |
| 05/02/2002 | US20020051799 Glucosylated hydroxystilbene compounds for treating skin conditions |
| 05/02/2002 | US20020051787 Steroids, viricides, and anti-microbial neutralizing antibodies suspended in a carrier |
| 05/02/2002 | US20020051782 Anti-CCR2 antibodies and methods of use therefor |
| 05/02/2002 | US20020051781 CC-chemokine receptor 2 (CCR2) bound by an immunoglobulin or an antigen-binding fragment |
| 05/02/2002 | US20020051766 Treating an aliquot of patient's blood ex vivo with a stressor selected from temperature above or below body temperature, an electromagnetic emission and an oxidative environment, followed by administering back into patient |
| 05/02/2002 | EP1201764A2 Assays for identifying phosphatase inhibitors |
| 05/02/2002 | EP1201757A2 Method for preparing water soluble polypeptides |
| 05/02/2002 | EP1201756A2 Method for preparing water soluble polypeptides |
| 05/02/2002 | EP1201679A2 Angiotensin I-converting enzyme inhibitory substance |
| 05/02/2002 | EP1201676A2 PNA-DNA-PNA chimeric macromolecules |
| 05/02/2002 | EP1201668A1 Staurosporin derivatives |
| 05/02/2002 | EP1201655A2 Process for the preparation of non-steroidal glucocorticoid receptor modulators |
| 05/02/2002 | EP1201649A1 Glucocorticoid receptor modulators |
| 05/02/2002 | EP1201268A2 Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors |
| 05/02/2002 | EP1201250A1 Immunogenic compositions comprising liver stage malarial antigens |
| 05/02/2002 | EP1201248A2 Combination therapy of angiotensin converting enzyme inhibitor, side-effect reduced amount of aldosterone antagonist and diuretic for treatment of cardiovascular disease |
| 05/02/2002 | EP1201239A1 Cyclic amine ccr3 antagonists |
| 05/02/2002 | EP1201237A1 Composition comprising an amide or a dialkylsulphoxide derivative for the treatment of cancer |
| 05/02/2002 | EP1201234A2 Treatment of diseases with adamantane derivates |
| 05/02/2002 | EP1201230A2 Solution-based transdermal drug delivery system comprising a vasodilator |
| 05/02/2002 | EP1201227A2 Use of flavonoids as immunomodulating or immunoprotecting agents in cosmetic and dermatological compositions |
| 05/02/2002 | EP1201137A1 Cysteine/glycine rich peptides |